Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy
Author: ["Pei-Lin Hsiung","Jonathan Hardy","Shai Friedland","Roy Soetikno","Christine B Du","Amy P Wu","Peyman Sahbaie","James M Crawford","Anson W Lowe","Christopher H Contag","Thomas D Wang"]
Publication: Nature Medicine
CITE.CC academic search helps you expand the influence of your papers.
Abstract
A combination of targeted probes and new imaging technologies provides a powerful set of tools with the potential to improve the early detection of cancer. To develop a probe for detecting colon cancer, we screened phage display peptide libraries against fresh human colonic adenomas for high-affinity ligands with preferential binding to premalignant tissue. We identified a specific heptapeptide sequence, VRPMPLQ, which we synthesized, conjugated with fluorescein and tested in patients undergoing colonoscopy. We imaged topically administered peptide using a fluorescence confocal microendoscope delivered through the instrument channel of a standard colonoscope. In vivo images were acquired at 12 frames per second with 50-μm working distance and 2.5-μm (transverse) and 20-μm (axial) resolution. The fluorescein-conjugated peptide bound more strongly to dysplastic colonocytes than to adjacent normal cells with 81% sensitivity and 82% specificity. This methodology represents a promising diagnostic imaging approach for the early detection of colorectal cancer and potentially of other epithelial malignancies.
Cite this article
Hsiung, PL., Hardy, J., Friedland, S. et al. Detection of colonic dysplasia in vivo using a targeted heptapeptide and confocal microendoscopy. Nat Med 14, 454–458 (2008). https://doi.org/10.1038/nm1692
